Edward Carr

Chief Financial Officer

Abeona Therapeutics Inc.Dianthus Therapeutics, Inc. /DE/

Insider activity · 24 months0 buys5 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 5 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (14 ops.)

€5.0M

Latest filing published 18 Sept 2026 for Dianthus Therapeutics, Inc. /DE/, €312k.

Filing timeline

BuySale

Edward Carr

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Edward Carr: trading record in brief

Filings by Edward Carr span 2 companies, the busiest being Dianthus Therapeutics, Inc. /DE/ and Abeona Therapeutics Inc. In total, 23 filings cover trades dated from 12 September 2019 to 17 September 2026.

The open-market record consists of 14 sales worth €5.0M, with no purchase. Outside the open market, there are 5 share grants and 4 option exercises. Since January 2026: no purchases and 10 sales on the market.

Most recently, on 18 September 2026, the filings show an option exercise worth €312k in Dianthus Therapeutics, Inc. /DE/. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.